CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $16.95M, above the global median of $16.24M
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.79BCNY561.87M · vs all stocks (USD)
Revenue (TTM)
381.71MCNY56.61M · vs all stocks (USD)
Profit Margin
-8.51%vs Biotechnology peers
Beta
0.2770xvs all stocks
52-Week Change
60.00%vs all stocks
Market Capitalization
3.79BCNY561.87M · vs all stocks (USD)
Enterprise Value
4.24BCNY629.03M · vs all stocks (USD)
Price to Sales (TTM)
10.95xvs Biotechnology peers
Price to Book (MRQ)
12.93xvs Biotechnology peers
Enterprise to Revenue
11.11xvs Biotechnology peers
Enterprise to EBITDA
-133.19xvs Biotechnology peers
Gross Margin
19.13%vs Biotechnology peers
Profit Margin
-8.51%vs Biotechnology peers
Operating Margin
-14.89%vs Biotechnology peers
Return on Assets (TTM)
-5.08%vs Biotechnology peers
Return on Equity (TTM)
-9.53%vs Biotechnology peers
Revenue (TTM)
381.71MCNY56.61M · vs all stocks (USD)
Revenue per Share (TTM)
0.3700CNYUpdated Aug 18, 2026Quarterly Revenue Growth
85.10%vs Biotechnology peers
Gross Profit (TTM)
109.53MCNY16.24M · vs all stocks (USD)
EBITDA (TTM)
-31.85MCNY-4.72M · vs all stocks (USD)
Net Income (TTM)
-32.49MCNY-4.82M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
70.80%vs Biotechnology peers
Operating Cash Flow (TTM)
52.57MCNY7.80M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
114.33MCNY16.95M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
24.74MCNYFY2025 · Dec 31, 2025Revenue
344.38MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
215.92MCNYFY2025 · Dec 31, 2025Gross Profit
128.46MCNYFY2025 · Dec 31, 2025Operating Income
-30.17MCNY-4.47M · vs all stocks (USD)
Pre-tax Income
-40.92MCNYFY2025 · Dec 31, 2025Income Tax Expense
-1.31MCNYFY2025 · Dec 31, 2025Net Income
-39.61MCNYFY2025 · Dec 31, 2025EBIT
-39.24MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-8.95MCNYFY2025 · Dec 31, 2025Research & Development
32.48MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
85.40MCNYFY2025 · Dec 31, 2025Other Operating Expenses
1.55MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
34.43KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.69MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0360CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0360CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.03BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.03BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-39.61MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.52MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
85.51MCNYFY2025 · Dec 31, 2025Free Cash Flow
82.00MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
79.69MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-39.61MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.69MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-13.10MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
136.53MCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.50MCNYFY2025 · Dec 31, 2025Net Acquisitions
5.03KCNYFY2025 · Dec 31, 2025Purchase of Investments
0.00CNYFY2025 · Dec 31, 2025Sale of Investments
1.50MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.00MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
10.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-9.47MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-575.20KCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.34MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-4.39MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.03BSharesUpdated Aug 18, 2026Float Shares
620.94MSharesUpdated Aug 18, 2026% Held by Insiders
44.36%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
75.12MCNY11.14M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0730CNYUpdated Aug 18, 2026Total Debt (MRQ)
40.90MCNY6.07M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1178xvs Biotechnology peers
Current Ratio (MRQ)
3.15xvs Biotechnology peers
Book Value per Share (MRQ)
0.3140CNYUpdated Aug 18, 2026Total Assets
494.04MCNY73.27M · vs all stocks (USD)
Total Current Assets
384.71MCNYFY2025 · Dec 31, 2025Total Liabilities
134.68MCNYFY2025 · Dec 31, 2025Total Non-current Assets
109.34MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
28.61MCNYFY2025 · Dec 31, 2025Total Current Liabilities
106.07MCNYFY2025 · Dec 31, 2025Cash
79.69MCNYFY2025 · Dec 31, 2025Cash Equivalents
9.86MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
89.55MCNYFY2025 · Dec 31, 2025Other Short-term Investments
139.88KCNYFY2025 · Dec 31, 2025Accounts Receivable
68.55MCNYFY2025 · Dec 31, 2025Inventory
218.87MCNYFY2025 · Dec 31, 2025Accounts Payable
44.54MCNYFY2025 · Dec 31, 2025Short-term Debt
15.04MCNYFY2025 · Dec 31, 2025Other Current Liabilities
20.93MCNYFY2025 · Dec 31, 2025Long-term Debt
15.11MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
13.41MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.03BCNYFY2025 · Dec 31, 2025Retained Earnings
-768.98MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
359.36MCNY53.29M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
2.22CNYUpdated Aug 18, 202652-Week High
4.54CNYUpdated Aug 18, 202652-Week Change
60.00%vs all stocks
Beta
0.2770xvs all stocks
50-Day MA
3.58CNYUpdated Aug 18, 2026200-Day MA
2.99CNYUpdated Aug 18, 2026Avg 10-Day Volume
64.39MSharesUpdated Aug 18, 2026Avg 30-Day Volume
65.49MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
-0.0300CNYUpdated Aug 18, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Elevated Inventory and Working Capital Buildup
The balance sheet has shrunk four years running, and inventory is much of what remains.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $16.95M, above the global median of $16.24MNotable
Levered free cash flow (USD): 16,954,975.277Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Careray Digital Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sinobioway Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shaanxi Kanghui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Boryung Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Harmony Biosciences Holdings, Inc.
4 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Infund Holding Co. Ltd.
2 interpretationsFCF Ratios ElevatedCash-Flow Ratios Elevated
CarGurus, Inc.
3 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital Elevated